Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, December 17, 2018
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Brazil with Eurofarma
Wednesday, December 12, 2018
GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics
Thursday, December 6, 2018
Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research
Thursday, November 29, 2018
Eisai: MOVICOL Launched in Japan
Wednesday, November 28, 2018
Eisai: Primary Endpoint Met in Phase III Clinical Study of Fycompa
Tuesday, November 27, 2018
Eisai to Present New Research on Eribulin (Halaven) at 41st Annual San Antonio Breast Cancer Symposium
Friday, November 23, 2018
Eisai to Present Latest Data on Perampanel at 72nd American Epilepsy Society Annual Meeting
Wednesday, November 14, 2018
Eisai Receives "IR Grand Prix Award"
Monday, November 12, 2018
Eisai Launches Lenvima (Lenvatinib) in China
Friday, November 9, 2018
Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: